| Name | Title | Contact Details |
|---|
The Bert Ogden Auto Group is the Rio Grande Valleys largest auto group. We proudly carry 19 different franchises out of 15 locations. We know that you have high expectations, and as a car dealer we enjoy the challenge of meeting and exceeding those standards with each and every customer interaction. Dale Gas!
Since 2000, INSBANK has offered its clients highly personalized service provided by experienced relationship managers, while positioning itself as an innovator, utilizing technologies to deliver those services efficiently and conveniently. In addition to its commercial focused operation, INSBANK operates three divisions, Medquity, TMA Medical Banking and INSBANK Online. Medquity offers healthcare banking solutions nationwide to healthcare companies and to individuals, whether they are still in residency, practicing or entering retirement, while TMA Medical Banking provides banking services specifically to members of the Tennessee Medical Association. INSBANK Online offers nationally available virtual private client services for interest bearing deposits. INSBANK is owned by InsCorp, Inc., a Tennessee bank holding company, traded on the OTCQX under symbol IBTN.
Biesse Group is a global leader in the design, manufacture, and distribution of machinery, integrated systems, components, and software for processing various materials, including wood, glass, stone, plastic, and metal. Founded in 1969 in Pesaro, Italy, the company has grown into a multinational enterprise with around 4,400 employees and a presence in 12 industrial sites and 39 subsidiaries worldwide. Biesse is listed on the STAR segment of the Italian Stock Exchange and exports 90% of its production. The company offers a wide range of solutions, including CNC machining centers, drilling machines, and automated systems tailored for different materials. Biesse emphasizes innovation and sustainability, investing €14 million annually in research and development and holding over 200-250 patents. Its advanced technologies incorporate AI and IoT, supporting industries such as furniture, construction, automotive, aerospace, and shipbuilding. Biesse also provides training and demonstrations through its global network of showrooms and campuses.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.